Search

Your search keyword '"Stricker, Bruno H"' showing total 2,207 results
Start Over Author "Stricker, Bruno H"
2,207 results on '"Stricker, Bruno H"'

3. Genetic architecture of spatial electrical biomarkers for cardiac arrhythmia and relationship with cardiovascular disease.

Author

Young, William J, Haessler, Jeffrey, Benjamins, Jan-Walter, Repetto, Linda, Yao, Jie, Isaacs, Aaron, Harper, Andrew R, Ramirez, Julia, Garnier, Sophie, van Duijvenboden, Stefan, Baldassari, Antoine R, Concas, Maria Pina, Duong, ThuyVy, Foco, Luisa, Isaksen, Jonas L, Mei, Hao, Noordam, Raymond, Nursyifa, Casia, Richmond, Anne, Santolalla, Meddly L, Sitlani, Colleen M, Soroush, Negin, Thériault, Sébastien, Trompet, Stella, Aeschbacher, Stefanie, Ahmadizar, Fariba, Alonso, Alvaro, Brody, Jennifer A, Campbell, Archie, Correa, Adolfo, Darbar, Dawood, De Luca, Antonio, Deleuze, Jean-François, Ellervik, Christina, Fuchsberger, Christian, Goel, Anuj, Grace, Christopher, Guo, Xiuqing, Hansen, Torben, Heckbert, Susan R, Jackson, Rebecca D, Kors, Jan A, Lima-Costa, Maria Fernanda, Linneberg, Allan, Macfarlane, Peter W, Morrison, Alanna C, Navarro, Pau, Porteous, David J, Pramstaller, Peter P, Reiner, Alexander P, Risch, Lorenz, Schotten, Ulrich, Shen, Xia, Sinagra, Gianfranco, Soliman, Elsayed Z, Stoll, Monika, Tarazona-Santos, Eduardo, Tinker, Andrew, Trajanoska, Katerina, Villard, Eric, Warren, Helen R, Whitsel, Eric A, Wiggins, Kerri L, Arking, Dan E, Avery, Christy L, Conen, David, Girotto, Giorgia, Grarup, Niels, Hayward, Caroline, Jukema, J Wouter, Mook-Kanamori, Dennis O, Olesen, Morten Salling, Padmanabhan, Sandosh, Psaty, Bruce M, Pattaro, Cristian, Ribeiro, Antonio Luiz P, Rotter, Jerome I, Stricker, Bruno H, van der Harst, Pim, van Duijn, Cornelia M, Verweij, Niek, Wilson, James G, Orini, Michele, Charron, Philippe, Watkins, Hugh, Kooperberg, Charles, Lin, Henry J, Wilson, James F, Kanters, Jørgen K, Sotoodehnia, Nona, Mifsud, Borbala, Lambiase, Pier D, Tereshchenko, Larisa G, and Munroe, Patricia B

Subjects
Humans, Cardiovascular Diseases, Electrocardiography, Risk Factors, Arrhythmias, Cardiac, Atrioventricular Block, Genome-Wide Association Study, Biomarkers, Human Genome, Cardiovascular, Genetics, Heart Disease
Abstract

The 3-dimensional spatial and 2-dimensional frontal QRS-T angles are measures derived from the vectorcardiogram. They are independent risk predictors for arrhythmia, but the underlying biology is unknown. Using multi-ancestry genome-wide association studies we identify 61 (58 previously unreported) loci for the spatial QRS-T angle (N = 118,780) and 11 for the frontal QRS-T angle (N = 159,715). Seven out of the 61 spatial QRS-T angle loci have not been reported for other electrocardiographic measures. Enrichments are observed in pathways related to cardiac and vascular development, muscle contraction, and hypertrophy. Pairwise genome-wide association studies with classical ECG traits identify shared genetic influences with PR interval and QRS duration. Phenome-wide scanning indicate associations with atrial fibrillation, atrioventricular block and arterial embolism and genetically determined QRS-T angle measures are associated with fascicular and bundle branch block (and also atrioventricular block for the frontal QRS-T angle). We identify potential biology involved in the QRS-T angle and their genetic relationships with cardiovascular traits and diseases, may inform future research and risk prediction.

Published
2023

9. Association of Systemic Medication Use with Glaucoma and Intraocular Pressure: The European Eye Epidemiology Consortium

Author

Vergroesen, Joëlle E., Schuster, Alexander K., Stuart, Kelsey V., Asefa, Nigus G., Cougnard-Grégoire, Audrey, Delcourt, Cécile, Schweitzer, Cédric, Barreto, Patrícia, Coimbra, Rita, Foster, Paul J., Luben, Robert N., Pfeiffer, Norbert, Stingl, Julia V., Kirsten, Toralf, Rauscher, Franziska G., Wirkner, Kerstin, Jansonius, Nomdo M., Arnould, Louis, Creuzot-Garcher, Catherine P., Stricker, Bruno H., Keskini, Christina, Topouzis, Fotis, Bertelsen, Geir, Eggen, Anne E., Bikbov, Mukharram M., Jonas, Jost B., Klaver, Caroline C.W., Ramdas, Wishal D., and Khawaja, Anthony P.

Published
2023
Full Text
View/download PDF

10. Genetic Determinants of Electrocardiographic P-Wave Duration and Relation to Atrial Fibrillation

Author

Weng, Lu-Chen, Hall, Amelia Weber, Choi, Seung Hoan, Jurgens, Sean J, Haessler, Jeffrey, Bihlmeyer, Nathan A, Grarup, Niels, Lin, Honghuang, Teumer, Alexander, Li-Gao, Ruifang, Yao, Jie, Guo, Xiuqing, Brody, Jennifer A, Müller-Nurasyid, Martina, Schramm, Katharina, Verweij, Niek, van den Berg, Marten E, van Setten, Jessica, Isaacs, Aaron, Ramírez, Julia, Warren, Helen R, Padmanabhan, Sandosh, Kors, Jan A, de Boer, Rudolf A, van der Meer, Peter, Sinner, Moritz F, Waldenberger, Melanie, Psaty, Bruce M, Taylor, Kent D, Völker, Uwe, Kanters, Jørgen K, Li, Man, Alonso, Alvaro, Perez, Marco V, Vaartjes, Ilonca, Bots, Michiel L, Huang, Paul L, Heckbert, Susan R, Lin, Henry J, Kornej, Jelena, Munroe, Patricia B, van Duijn, Cornelia M, Asselbergs, Folkert W, Stricker, Bruno H, van der Harst, Pim, Kääb, Stefan, Peters, Annette, Sotoodehnia, Nona, Rotter, Jerome I, Mook-Kanamori, Dennis O, Dörr, Marcus, Felix, Stephan B, Linneberg, Allan, Hansen, Torben, Arking, Dan E, Kooperberg, Charles, Benjamin, Emelia J, Lunetta, Kathryn L, Ellinor, Patrick T, and Lubitz, Steven A

Subjects
Biomedical and Clinical Sciences, Cardiovascular Medicine and Haematology, Clinical Research, Genetics, Heart Disease, Cardiovascular, Human Genome, 2.1 Biological and endogenous factors, Aetiology, Atrial Fibrillation, Cardiac Myosins, Connectin, Electrocardiography, Genetic Variation, Genome-Wide Association Study, Homeodomain Proteins, Humans, Myosin Heavy Chains, NAV1.8 Voltage-Gated Sodium Channel, Quantitative Trait Loci, Transcription Factors, atrial fibrillation, electrophysiology, exome, genetic, genome-wide association studies, population, Medical Biotechnology, Cardiorespiratory Medicine and Haematology, Cardiovascular System & Hematology, Cardiovascular medicine and haematology
Abstract

BackgroundThe P-wave duration (PWD) is an electrocardiographic measurement that represents cardiac conduction in the atria. Shortened or prolonged PWD is associated with atrial fibrillation (AF). We used exome-chip data to examine the associations between common and rare variants with PWD.MethodsFifteen studies comprising 64 440 individuals (56 943 European, 5681 African, 1186 Hispanic, 630 Asian) and ≈230 000 variants were used to examine associations with maximum PWD across the 12-lead ECG. Meta-analyses summarized association results for common variants; gene-based burden and sequence kernel association tests examined low-frequency variant-PWD associations. Additionally, we examined the associations between PWD loci and AF using previous AF genome-wide association studies.ResultsWe identified 21 common and low-frequency genetic loci (14 novel) associated with maximum PWD, including several AF loci (TTN, CAND2, SCN10A, PITX2, CAV1, SYNPO2L, SOX5, TBX5, MYH6, RPL3L). The top variants at known sarcomere genes (TTN, MYH6) were associated with longer PWD and increased AF risk. However, top variants at other loci (eg, PITX2 and SCN10A) were associated with longer PWD but lower AF risk.ConclusionsOur results highlight multiple novel genetic loci associated with PWD, and underscore the shared mechanisms of atrial conduction and AF. Prolonged PWD may be an endophenotype for several different genetic mechanisms of AF.

Published
2020

13. Genome-wide meta-analysis of SNP-by9-ACEI/ARB and SNP-by-thiazide diuretic and effect on serum potassium in cohorts of European and African ancestry

Author

Irvin, Marguerite R, Sitlani, Colleen M, Noordam, Raymond, Avery, Christie L, Bis, Joshua C, Floyd, James S, Li, Jin, Limdi, Nita A, Srinivasasainagendra, Vinodh, Stewart, James, de Mutsert, Renée, Mook-Kanamori, Dennis O, Lipovich, Leonard, Kleinbrink, Erica L, Smith, Albert, Bartz, Traci M, Whitsel, Eric A, Uitterlinden, Andre G, Wiggins, Kerri L, Wilson, James G, Zhi, Degui, Stricker, Bruno H, Rotter, Jerome I, Arnett, Donna K, Psaty, Bruce M, and Lange, Leslie A

Subjects
Pharmacology and Pharmaceutical Sciences, Biomedical and Clinical Sciences, Health Disparities, Human Genome, Genetics, Prevention, Minority Health, Black or African American, Aged, Antihypertensive Agents, Chromosomes, Human, Pair 5, Europe, Female, Genome-Wide Association Study, Genotype, Humans, Male, Middle Aged, Peptidyl-Dipeptidase A, Polymorphism, Single Nucleotide, Potassium, Sodium Chloride Symporter Inhibitors, White People, Pharmacology & Pharmacy, Pharmacology and pharmaceutical sciences
Abstract

We evaluated interactions of SNP-by-ACE-I/ARB and SNP-by-TD on serum potassium (K+) among users of antihypertensive treatments (anti-HTN). Our study included seven European-ancestry (EA) (N = 4835) and four African-ancestry (AA) cohorts (N = 2016). We performed race-stratified, fixed-effect, inverse-variance-weighted meta-analyses of 2.5 million SNP-by-drug interaction estimates; race-combined meta-analysis; and trans-ethnic fine-mapping. Among EAs, we identified 11 significant SNPs (P

Published
2019

17. Meta-analysis across Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium provides evidence for an association of serum vitamin D with pulmonary function

Author

Xu, Jiayi, Bartz, Traci M, Chittoor, Geetha, Eiriksdottir, Gudny, Manichaikul, Ani W, Sun, Fangui, Terzikhan, Natalie, Zhou, Xia, Booth, Sarah L, Brusselle, Guy G, de Boer, Ian H, Fornage, Myriam, Frazier-Wood, Alexis C, Graff, Mariaelisa, Gudnason, Vilmundur, Harris, Tamara B, Hofman, Albert, Hou, Ruixue, Houston, Denise K, Jacobs, David R, Kritchevsky, Stephen B, Latourelle, Jeanne, Lemaitre, Rozenn N, Lutsey, Pamela L, O’Connor, George, Oelsner, Elizabeth C, Pankow, James S, Psaty, Bruce M, Rohde, Rebecca R, Rich, Stephen S, Rotter, Jerome I, Smith, Lewis J, Stricker, Bruno H, Voruganti, V Saroja, Wang, Thomas J, Zillikens, M Carola, Barr, R Graham, Dupuis, Josée, Gharib, Sina A, Lahousse, Lies, London, Stephanie J, North, Kari E, Smith, Albert V, Steffen, Lyn M, Hancock, Dana B, and Cassano, Patricia A

Subjects
Biomedical and Clinical Sciences, Nutrition and Dietetics, Complementary and Integrative Health, Aging, Clinical Research, Adult, Aged, Black People, Cross-Sectional Studies, Female, Forced Expiratory Volume, Genome, Human, Heart, Heart Diseases, Humans, Lung, Lung Diseases, Male, Middle Aged, Molecular Epidemiology, Prospective Studies, Regression Analysis, Respiratory Function Tests, Smoking, Vital Capacity, Vitamin D, White People, 1, 25(OH)D 25-hydroxyvitamin D, AA African ancestry, AGES Age, ARIC Atherosclerosis Risk in Communities Study, Aging, CARDIA Coronary Artery Risk Development in Young Adults Study, CHARGE Cohorts for Heart and Aging Research in Genomic Epidemiology, CHS Cardiovascular Health Study, COPD chronic obstructive pulmonary disease, EA European ancestry, Environment, FEV1 forced expiratory volume in the 1st second, FHS (Gen3) Framingham Heart Study – Generation 3 Cohort, FHS (Offspring) Framingham Heart Study –Offspring Cohort, FVC forced vital capacity, Gene, HABC Health, Iceland, MESA Multi-Ethnic Study of Atherosclerosis, PFT pulmonary function test, RIA radioimmunoassay, Susceptibility Study − Reykjavik, and Body Composition Study, 25-(OH)2D 1, 25-dihydroxyvitamin D, African Americans, Forced expiratory volume, Respiratory function tests, Vital capacity, Whites, Animal Production, Food Sciences, Nutrition & Dietetics, Animal production, Food sciences, Nutrition and dietetics
Abstract

The role that vitamin D plays in pulmonary function remains uncertain. Epidemiological studies reported mixed findings for serum 25-hydroxyvitamin D (25(OH)D)-pulmonary function association. We conducted the largest cross-sectional meta-analysis of the 25(OH)D-pulmonary function association to date, based on nine European ancestry (EA) cohorts (n 22 838) and five African ancestry (AA) cohorts (n 4290) in the Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium. Data were analysed using linear models by cohort and ancestry. Effect modification by smoking status (current/former/never) was tested. Results were combined using fixed-effects meta-analysis. Mean serum 25(OH)D was 68 (sd 29) nmol/l for EA and 49 (sd 21) nmol/l for AA. For each 1 nmol/l higher 25(OH)D, forced expiratory volume in the 1st second (FEV1) was higher by 1·1 ml in EA (95 % CI 0·9, 1·3; P

Published
2018

20. Objectives, design and main findings until 2020 from the Rotterdam Study

Author

Ikram, M. Arfan, Brusselle, Guy, Ghanbari, Mohsen, Goedegebure, André, Ikram, M. Kamran, Kavousi, Maryam, Kieboom, Brenda C. T., Klaver, Caroline C. W., de Knegt, Robert J., Luik, Annemarie I., Nijsten, Tamar E. C., Peeters, Robin P., van Rooij, Frank J. A., Stricker, Bruno H., Uitterlinden, André G., Vernooij, Meike W., and Voortman, Trudy

Published
2020

22. Large-scale genome-wide analysis identifies genetic variants associated with cardiac structure and function

Author

Wild, Philipp S, Felix, Janine F, Schillert, Arne, Teumer, Alexander, Chen, Ming-Huei, Leening, Maarten JG, Völker, Uwe, Großmann, Vera, Brody, Jennifer A, Irvin, Marguerite R, Shah, Sanjiv J, Pramana, Setia, Lieb, Wolfgang, Schmidt, Reinhold, Stanton, Alice V, Malzahn, Dörthe, Smith, Albert Vernon, Sundström, Johan, Minelli, Cosetta, Ruggiero, Daniela, Lyytikäinen, Leo-Pekka, Tiller, Daniel, Smith, J Gustav, Monnereau, Claire, Di Tullio, Marco R, Musani, Solomon K, Morrison, Alanna C, Pers, Tune H, Morley, Michael, Kleber, Marcus E, Aragam, Jayashri, Benjamin, Emelia J, Bis, Joshua C, Bisping, Egbert, Broeckel, Ulrich, Cheng, Susan, Deckers, Jaap W, Del Greco M, Fabiola, Edelmann, Frank, Fornage, Myriam, Franke, Lude, Friedrich, Nele, Harris, Tamara B, Hofer, Edith, Hofman, Albert, Huang, Jie, Hughes, Alun D, Kähönen, Mika, investigators, KNHI, Kruppa, Jochen, Lackner, Karl J, Lannfelt, Lars, Laskowski, Rafael, Launer, Lenore J, Leosdottir, Margrét, Lin, Honghuang, Lindgren, Cecilia M, Loley, Christina, MacRae, Calum A, Mascalzoni, Deborah, Mayet, Jamil, Medenwald, Daniel, Morris, Andrew P, Müller, Christian, Müller-Nurasyid, Martina, Nappo, Stefania, Nilsson, Peter M, Nuding, Sebastian, Nutile, Teresa, Peters, Annette, Pfeufer, Arne, Pietzner, Diana, Pramstaller, Peter P, Raitakari, Olli T, Rice, Kenneth M, Rivadeneira, Fernando, Rotter, Jerome I, Ruohonen, Saku T, Sacco, Ralph L, Samdarshi, Tandaw E, Schmidt, Helena, Sharp, Andrew SP, Shields, Denis C, Sorice, Rossella, Sotoodehnia, Nona, Stricker, Bruno H, Surendran, Praveen, Thom, Simon, Töglhofer, Anna M, Uitterlinden, André G, Wachter, Rolf, Völzke, Henry, Ziegler, Andreas, Münzel, Thomas, März, Winfried, Cappola, Thomas P, Hirschhorn, Joel N, Mitchell, Gary F, Smith, Nicholas L, and Fox, Ervin R

Subjects
Biological Sciences, Biomedical and Clinical Sciences, Genetics, Human Genome, Clinical Research, Prevention, Heart Disease, Cardiovascular, 2.1 Biological and endogenous factors, Aetiology, Female, Genetic Loci, Genome-Wide Association Study, Heart Diseases, Humans, Male, Myocardium, Polymorphism, Single Nucleotide, Quantitative Trait, Heritable, Medical and Health Sciences, Immunology, Biological sciences, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundUnderstanding the genetic architecture of cardiac structure and function may help to prevent and treat heart disease. This investigation sought to identify common genetic variations associated with inter-individual variability in cardiac structure and function.MethodsA GWAS meta-analysis of echocardiographic traits was performed, including 46,533 individuals from 30 studies (EchoGen consortium). The analysis included 16 traits of left ventricular (LV) structure, and systolic and diastolic function.ResultsThe discovery analysis included 21 cohorts for structural and systolic function traits (n = 32,212) and 17 cohorts for diastolic function traits (n = 21,852). Replication was performed in 5 cohorts (n = 14,321) and 6 cohorts (n = 16,308), respectively. Besides 5 previously reported loci, the combined meta-analysis identified 10 additional genome-wide significant SNPs: rs12541595 near MTSS1 and rs10774625 in ATXN2 for LV end-diastolic internal dimension; rs806322 near KCNRG, rs4765663 in CACNA1C, rs6702619 near PALMD, rs7127129 in TMEM16A, rs11207426 near FGGY, rs17608766 in GOSR2, and rs17696696 in CFDP1 for aortic root diameter; and rs12440869 in IQCH for Doppler transmitral A-wave peak velocity. Findings were in part validated in other cohorts and in GWAS of related disease traits. The genetic loci showed associations with putative signaling pathways, and with gene expression in whole blood, monocytes, and myocardial tissue.ConclusionThe additional genetic loci identified in this large meta-analysis of cardiac structure and function provide insights into the underlying genetic architecture of cardiac structure and warrant follow-up in future functional studies.FundingFor detailed information per study, see Acknowledgments.

Published
2017

23. A genome-wide interaction analysis of tricyclic/tetracyclic antidepressants and RR and QT intervals: a pharmacogenomics study from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium

Author

Noordam, Raymond, Sitlani, Colleen M, Avery, Christy L, Stewart, James D, Gogarten, Stephanie M, Wiggins, Kerri L, Trompet, Stella, Warren, Helen R, Sun, Fangui, Evans, Daniel S, Li, Xiaohui, Li, Jin, Smith, Albert V, Bis, Joshua C, Brody, Jennifer A, Busch, Evan L, Caulfield, Mark J, Chen, Yii-Der I, Cummings, Steven R, Cupples, L Adrienne, Duan, Qing, Franco, Oscar H, Méndez-Giráldez, Rául, Harris, Tamara B, Heckbert, Susan R, van Heemst, Diana, Hofman, Albert, Floyd, James S, Kors, Jan A, Launer, Lenore J, Li, Yun, Li-Gao, Ruifang, Lange, Leslie A, Lin, Henry J, de Mutsert, Renée, Napier, Melanie D, Newton-Cheh, Christopher, Poulter, Neil, Reiner, Alexander P, Rice, Kenneth M, Roach, Jeffrey, Rodriguez, Carlos J, Rosendaal, Frits R, Sattar, Naveed, Sever, Peter, Seyerle, Amanda A, Slagboom, P Eline, Soliman, Elsayed Z, Sotoodehnia, Nona, Stott, David J, Stürmer, Til, Taylor, Kent D, Thornton, Timothy A, Uitterlinden, André G, Wilhelmsen, Kirk C, Wilson, James G, Gudnason, Vilmundur, Jukema, J Wouter, Laurie, Cathy C, Liu, Yongmei, Mook-Kanamori, Dennis O, Munroe, Patricia B, Rotter, Jerome I, Vasan, Ramachandran S, Psaty, Bruce M, Stricker, Bruno H, and Whitsel, Eric A

Subjects
Pharmacology and Pharmaceutical Sciences, Biological Sciences, Biomedical and Clinical Sciences, Genetics, Health Disparities, Human Genome, Minority Health, Cardiovascular, Heart Disease, Good Health and Well Being, Aged, Aging, Antidepressive Agents, Tricyclic, Electrocardiography, Female, Genetic Loci, Genome-Wide Association Study, Heart, Humans, Male, Middle Aged, Pharmacogenetics, Genome-wide, QT interval electrocardiography, RR interval, drug-gene interaction, tri/tetracyclic antidepressants, Medical and Health Sciences, Genetics & Heredity, Clinical sciences
Abstract

BackgroundIncreased heart rate and a prolonged QT interval are important risk factors for cardiovascular morbidity and mortality, and can be influenced by the use of various medications, including tricyclic/tetracyclic antidepressants (TCAs). We aim to identify genetic loci that modify the association between TCA use and RR and QT intervals.Methods and resultsWe conducted race/ethnic-specific genome-wide interaction analyses (with HapMap phase II imputed reference panel imputation) of TCAs and resting RR and QT intervals in cohorts of European (n=45 706; n=1417 TCA users), African (n=10 235; n=296 TCA users) and Hispanic/Latino (n=13 808; n=147 TCA users) ancestry, adjusted for clinical covariates. Among the populations of European ancestry, two genome-wide significant loci were identified for RR interval: rs6737205 in BRE (β=56.3, pinteraction=3.9e-9) and rs9830388 in UBE2E2 (β=25.2, pinteraction=1.7e-8). In Hispanic/Latino cohorts, rs2291477 in TGFBR3 significantly modified the association between TCAs and QT intervals (β=9.3, pinteraction=2.55e-8). In the meta-analyses of the other ethnicities, these loci either were excluded from the meta-analyses (as part of quality control), or their effects did not reach the level of nominal statistical significance (pinteraction>0.05). No new variants were identified in these ethnicities. No additional loci were identified after inverse-variance-weighted meta-analysis of the three ancestries.ConclusionsAmong Europeans, TCA interactions with variants in BRE and UBE2E2 were identified in relation to RR intervals. Among Hispanic/Latinos, variants in TGFBR3 modified the relation between TCAs and QT intervals. Future studies are required to confirm our results.

Published
2017

24. Genetic loci associated with chronic obstructive pulmonary disease overlap with loci for lung function and pulmonary fibrosis

Author

Hobbs, Brian D, de Jong, Kim, Lamontagne, Maxime, Bossé, Yohan, Shrine, Nick, Artigas, María Soler, Wain, Louise V, Hall, Ian P, Jackson, Victoria E, Wyss, Annah B, London, Stephanie J, North, Kari E, Franceschini, Nora, Strachan, David P, Beaty, Terri H, Hokanson, John E, Crapo, James D, Castaldi, Peter J, Chase, Robert P, Bartz, Traci M, Heckbert, Susan R, Psaty, Bruce M, Gharib, Sina A, Zanen, Pieter, Lammers, Jan W, Oudkerk, Matthijs, Groen, HJ, Locantore, Nicholas, Tal-Singer, Ruth, Rennard, Stephen I, Vestbo, Jørgen, Timens, Wim, Paré, Peter D, Latourelle, Jeanne C, Dupuis, Josée, O'Connor, George T, Wilk, Jemma B, Kim, Woo Jin, Lee, Mi Kyeong, Oh, Yeon-Mok, Vonk, Judith M, de Koning, Harry J, Leng, Shuguang, Belinsky, Steven A, Tesfaigzi, Yohannes, Manichaikul, Ani, Wang, Xin-Qun, Rich, Stephen S, Barr, R Graham, Sparrow, David, Litonjua, Augusto A, Bakke, Per, Gulsvik, Amund, Lahousse, Lies, Brusselle, Guy G, Stricker, Bruno H, Uitterlinden, André G, Ampleford, Elizabeth J, Bleecker, Eugene R, Woodruff, Prescott G, Meyers, Deborah A, Qiao, Dandi, Lomas, David A, Yim, Jae-Joon, Kim, Deog Kyeom, Hawrylkiewicz, Iwona, Sliwinski, Pawel, Hardin, Megan, Fingerlin, Tasha E, Schwartz, David A, Postma, Dirkje S, MacNee, William, Tobin, Martin D, Silverman, Edwin K, Boezen, H Marike, and Cho, Michael H

Subjects
Biological Sciences, Genetics, Chronic Obstructive Pulmonary Disease, Lung, Human Genome, Clinical Research, Aetiology, 2.1 Biological and endogenous factors, Respiratory, Adult, Aged, Aged, 80 and over, Alleles, Asthma, Female, Genetic Loci, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Male, Middle Aged, Phenotype, Polymorphism, Single Nucleotide, Pulmonary Disease, Chronic Obstructive, Pulmonary Fibrosis, Risk Factors, Smoking, COPDGene Investigators, ECLIPSE Investigators, LifeLines Investigators, SPIROMICS Research Group, International COPD Genetics Network Investigators, UK BiLEVE Investigators, International COPD Genetics Consortium, Medical and Health Sciences, Developmental Biology, Agricultural biotechnology, Bioinformatics and computational biology
Abstract

Chronic obstructive pulmonary disease (COPD) is a leading cause of mortality worldwide. We performed a genetic association study in 15,256 cases and 47,936 controls, with replication of select top results (P < 5 × 10-6) in 9,498 cases and 9,748 controls. In the combined meta-analysis, we identified 22 loci associated at genome-wide significance, including 13 new associations with COPD. Nine of these 13 loci have been associated with lung function in general population samples, while 4 (EEFSEC, DSP, MTCL1, and SFTPD) are new. We noted two loci shared with pulmonary fibrosis (FAM13A and DSP) but that had opposite risk alleles for COPD. None of our loci overlapped with genome-wide associations for asthma, although one locus has been implicated in joint susceptibility to asthma and obesity. We also identified genetic correlation between COPD and asthma. Our findings highlight new loci associated with COPD, demonstrate the importance of specific loci associated with lung function to COPD, and identify potential regions of genetic overlap between COPD and other respiratory diseases.

Published
2017

25. Genetic Interactions with Age, Sex, Body Mass Index, and Hypertension in Relation to Atrial Fibrillation: The AFGen Consortium

Author

Weng, Lu-Chen, Lunetta, Kathryn L, Müller-Nurasyid, Martina, Smith, Albert Vernon, Thériault, Sébastien, Weeke, Peter E, Barnard, John, Bis, Joshua C, Lyytikäinen, Leo-Pekka, Kleber, Marcus E, Martinsson, Andreas, Lin, Henry J, Rienstra, Michiel, Trompet, Stella, Krijthe, Bouwe P, Dörr, Marcus, Klarin, Derek, Chasman, Daniel I, Sinner, Moritz F, Waldenberger, Melanie, Launer, Lenore J, Harris, Tamara B, Soliman, Elsayed Z, Alonso, Alvaro, Paré, Guillaume, Teixeira, Pedro L, Denny, Joshua C, Shoemaker, M Benjamin, Van Wagoner, David R, Smith, Jonathan D, Psaty, Bruce M, Sotoodehnia, Nona, Taylor, Kent D, Kähönen, Mika, Nikus, Kjell, Delgado, Graciela E, Melander, Olle, Engström, Gunnar, Yao, Jie, Guo, Xiuqing, Christophersen, Ingrid E, Ellinor, Patrick T, Geelhoed, Bastiaan, Verweij, Niek, Macfarlane, Peter, Ford, Ian, Heeringa, Jan, Franco, Oscar H, Uitterlinden, André G, Völker, Uwe, Teumer, Alexander, Rose, Lynda M, Kääb, Stefan, Gudnason, Vilmundur, Arking, Dan E, Conen, David, Roden, Dan M, Chung, Mina K, Heckbert, Susan R, Benjamin, Emelia J, Lehtimäki, Terho, März, Winfried, Smith, J Gustav, Rotter, Jerome I, van der Harst, Pim, Jukema, J Wouter, Stricker, Bruno H, Felix, Stephan B, Albert, Christine M, and Lubitz, Steven A

Subjects
Epidemiology, Biological Sciences, Health Sciences, Genetics, Heart Disease, Cardiovascular, Prevention, Human Genome, 2.1 Biological and endogenous factors, Aetiology, Age Factors, Aged, Atrial Fibrillation, Body Mass Index, Chromosomes, Human, Pair 4, Epistasis, Genetic, Female, Genetic Loci, Genetic Predisposition to Disease, Genome-Wide Association Study, Humans, Hypertension, Male, Middle Aged, Odds Ratio, Polymorphism, Single Nucleotide, Reproducibility of Results, Risk Factors, Sex Characteristics
Abstract

It is unclear whether genetic markers interact with risk factors to influence atrial fibrillation (AF) risk. We performed genome-wide interaction analyses between genetic variants and age, sex, hypertension, and body mass index in the AFGen Consortium. Study-specific results were combined using meta-analysis (88,383 individuals of European descent, including 7,292 with AF). Variants with nominal interaction associations in the discovery analysis were tested for association in four independent studies (131,441 individuals, including 5,722 with AF). In the discovery analysis, the AF risk associated with the minor rs6817105 allele (at the PITX2 locus) was greater among subjects ≤ 65 years of age than among those > 65 years (interaction p-value = 4.0 × 10-5). The interaction p-value exceeded genome-wide significance in combined discovery and replication analyses (interaction p-value = 1.7 × 10-8). We observed one genome-wide significant interaction with body mass index and several suggestive interactions with age, sex, and body mass index in the discovery analysis. However, none was replicated in the independent sample. Our findings suggest that the pathogenesis of AF may differ according to age in individuals of European descent, but we did not observe evidence of statistically significant genetic interactions with sex, body mass index, or hypertension on AF risk.

Published
2017

27. Statin therapy and cardiovascular protection in type 2 diabetes: The role of baseline LDL-Cholesterol levels. A systematic review and meta-analysis of observational studies

Author

RWE/Causal inference, Child Health, Soroush, Negin, Nekouei Shahraki, Mitra, Mohammadi Jouabadi, Soroush, Amiri, Masoud, Aribas, Elif, Stricker, Bruno H, Ahmadizar, Fariba, RWE/Causal inference, Child Health, Soroush, Negin, Nekouei Shahraki, Mitra, Mohammadi Jouabadi, Soroush, Amiri, Masoud, Aribas, Elif, Stricker, Bruno H, and Ahmadizar, Fariba

Published
2024

28. Benzodiazepine use in relation to long-term dementia risk and imaging markers of neurodegeneration:a population-based study

Author

Hofe, Ilse vom, Stricker, Bruno H., Vernooij, Meike W., Ikram, M. Kamran, Ikram, M. Arfan, Wolters, Frank J., Hofe, Ilse vom, Stricker, Bruno H., Vernooij, Meike W., Ikram, M. Kamran, Ikram, M. Arfan, and Wolters, Frank J.

Abstract

Background: Benzodiazepine use is common, particularly in older adults. Benzodiazepines have well-established acute adverse effects on cognition, but long-term effects on neurodegeneration and dementia risk remain uncertain. Methods: We included 5443 cognitively healthy (MMSE ≥ 26) participants from the population-based Rotterdam Study (57.4% women, mean age 70.6 years). Benzodiazepine use from 1991 until baseline (2005–2008) was derived from pharmacy dispensing records, from which we determined drug type and cumulative dose. Benzodiazepine use was defined as prescription of anxiolytics (ATC-code: N05BA) or sedative-hypnotics (ATC-code: N05CD) between inception of pharmacy records and study baseline. Cumulative dose was calculated as the sum of the defined daily doses for all prescriptions. We determined the association with dementia risk until 2020 using Cox regression. Among 4836 participants with repeated brain MRI, we further determined the association of benzodiazepine use with changes in neuroimaging markers using linear mixed models. Results: Of all 5443 participants, 2697 (49.5%) had used benzodiazepines at any time in the 15 years preceding baseline, of whom 1263 (46.8%) used anxiolytics, 530 (19.7%) sedative-hypnotics, and 904 (33.5%) used both; 345 (12.8%) participants were still using at baseline assessment. During a mean follow-up of 11.2 years, 726 participants (13.3%) developed dementia. Overall, use of benzodiazepines was not associated with dementia risk compared to never use (HR [95% CI]: 1.06 [0.90–1.25]), irrespective of cumulative dose. Risk estimates were somewhat higher for any use of anxiolytics than for sedative-hypnotics (HR 1.17 [0.96–1.41] vs 0.92 [0.70–1.21]), with strongest associations for high cumulative dose of anxiolytics (HR [95% CI] 1.33 [1.04–1.71]). In imaging analyses, current use of benzodiazepine was associated cross-sectionally with lower brain volumes of the hippocampus, amygdala, and thalamus and longitudinally with acc

Published
2024

29. Statin therapy and cardiovascular protection in type 2 diabetes:The role of baseline LDL-Cholesterol levels. A systematic review and meta-analysis of observational studies

Author

Soroush, Negin, Nekouei Shahraki, Mitra, Mohammadi Jouabadi, Soroush, Amiri, Masoud, Aribas, Elif, Stricker, Bruno H., Ahmadizar, Fariba, Soroush, Negin, Nekouei Shahraki, Mitra, Mohammadi Jouabadi, Soroush, Amiri, Masoud, Aribas, Elif, Stricker, Bruno H., and Ahmadizar, Fariba

Abstract

Aim: The guidelines recommend statins to prevent cardiovascular events in patients with type 2 diabetes (T2D) however, the importance of baseline LDL-Cholesterol (LDL-C) levels remains controversial. This study aimed to determine the association of statin use in T2D patients with major adverse cardiovascular events (MACE) and all-cause mortality and whether this association differs by baseline LDL-C levels. Data synthesis: Medline, Embase, and Web of Science were systematically searched from inception until January 2022. Observational studies in patients with T2D comparing statin users vs non-users, with reports of the baseline LDL-C levels, were included. Random-effects meta-analysis and meta-regression were performed to estimate the overall effect on the risk of all-cause mortality and MACE (a composite of myocardial infarction, heart failure, stroke, and revascularization events) and the modification in the association by baseline LDL-C levels. We categorized studies according to their baseline LDL-C levels into 1) <100 mg/dl (2.59 mmol/l), 2) 100–130 mg/dl (2.59–3.37 mmol/l) and 3) >130 mg/dl (3.37 mmol/l) categories. A total of 9 cohort studies (n = 403,411 individuals) fulfilled our criteria. The follow-up duration ranged from 1.7 to 8 years. The overall combined estimate showed that statin therapy was associated with a significantly lower risk of MACE (Hazard Ratio (HR): 0.70 [95% CI 0.59 to 0.83], Absolute risk reduction percentage (ARR%): 3.19% [95%CI 0.88 to 5.50%) and all-cause mortality (HR: 0.60 [95% CI 0.46 to 0.79], ARR%: 5.23% [95% CI 2.18 to 8.28%), but varied, albeit not statistically significant, by baseline LDL-C levels. Studies with baseline LDL-C levels higher than 130 mg/dl had the greatest reduction of MACE (HR: 0.58 [95% CI 0.37 to 0.90]) and all-cause mortality risk (HR: 0.51 [95% CI [ 0.29 to 0.90]). The HRs of MACE in studies with LDL-C levels of 100–130 mg/dl and <100 mg/dl categories were r

Published
2024

30. Antidepressant use in relation to dementia risk, cognitive decline, and brain atrophy

Author

vom Hofe, Ilse, Stricker, Bruno H., Vernooij, Meike W., Ikram, M. Kamran, Ikram, M. Arfan, Wolters, Frank J., vom Hofe, Ilse, Stricker, Bruno H., Vernooij, Meike W., Ikram, M. Kamran, Ikram, M. Arfan, and Wolters, Frank J.

Abstract

INTRODUCTION: We aimed to assess the effect of antidepressant use on dementia risk, cognitive decline, and brain atrophy. METHODS: In this prospective cohort study, we included 5511 dementia-free participants (Mini-Mental State Examination [MMSE] > 25) of the Rotterdam study (57.5% women, mean age 70.6 years). Antidepressant use was extracted from pharmacy records from 1991 until baseline (2002–2008). Incident dementia was monitored from baseline until 2018, with repeated cognitive assessment and magnetic resonance imaging (MRI) every 4 years. RESULTS: Compared to never use, any antidepressant use was not associated with dementia risk (hazard ratio [HR] 1.14, 95% confidence interval [CI] 0.92–1.41), or with accelerated cognitive decline or atrophy of white and gray matter. Compared to never use, dementia risk was somewhat higher with tricyclic antidepressants (HR 1.36, 95% CI 1.01–1.83) than with selective serotonin reuptake inhibitors (HR 1.12, 95% CI 0.81–1.54), but without dose–response relationships, accelerated cognitive decline, or atrophy in either group. DISCUSSION: Antidepressant medication in adults without indication of cognitive impairment was not consistently associated with long-term adverse cognitive effects. Highlights: Antidepressant medications are frequently prescribed, especially among older adults. In this study, antidepressant use was not associated with long-term dementia risk. Antidepressant use was not associated with cognitive decline or brain atrophy. Our results support safe prescription in an older, cognitively healthy population.

Published
2024

31. Gene-based association analysis of a large patient cohort provides insights into genetics of atypical femur fractures

Author

Zhou, Wei, Ås, Joel, Shore-Lorenti, Catherine, Nguyen, Hanh H., van de Laarschot, Denise M., Sztal-Mazer, Shoshana, Grill, Vivian, Girgis, Christian M., Stricker, Bruno H. Ch., van der Eerden, Bram C. J., Thakker, Rajesh V., Appelman-Dijkstra, Natasha M., Wadelius, Mia, Clifton-Bligh, Roderick J., Hallberg, Pär, Verkerk, Annemieke J. M. H., van Rooij, Jeroen G. J., Ebeling, Peter R., Zillikens, M. Carola, Zhou, Wei, Ås, Joel, Shore-Lorenti, Catherine, Nguyen, Hanh H., van de Laarschot, Denise M., Sztal-Mazer, Shoshana, Grill, Vivian, Girgis, Christian M., Stricker, Bruno H. Ch., van der Eerden, Bram C. J., Thakker, Rajesh V., Appelman-Dijkstra, Natasha M., Wadelius, Mia, Clifton-Bligh, Roderick J., Hallberg, Pär, Verkerk, Annemieke J. M. H., van Rooij, Jeroen G. J., Ebeling, Peter R., and Zillikens, M. Carola

Abstract

Several small genetic association studies have been conducted for atypical femur fracture (AFF) without replication of results. We assessed previously implicated and novel genes associated with AFFs in a larger set of unrelated AFF cases using whole exome sequencing (WES). We performed gene-based association analysis on 139 European AFF cases and 196 controls matched for bisphosphonate use. We tested all rare, protein-altering variants using both candidate gene and hypothesis-free approaches. In the latter, genes suggestively associated with AFFs (uncorrected p-values <.01) were investigated in a Swedish whole-genome sequencing replication study and assessed in 46 non-European cases. In the candidate gene analysis, PLOD2 showed a suggestive signal. The hypothesis-free approach revealed 10 tentative associations, with XRN2, SORD, and PLOD2 being the most likely candidates for AFF. XRN2 and PLOD2 showed consistent direction of effect estimates in the replication analysis, albeit not statistically significant. Three SNPs associated with SORD expression according to the GTEx portal were in linkage disequilibrium (R2 ≥ 0.2) with an SNP previously reported in a genome-wide association study of AFF. The prevalence of carriers of variants for both PLOD2 and SORD was higher in Asian versus European cases. While we did not identify genes enriched for damaging variants, we found suggestive evidence of a role for XRN2, PLOD2, and SORD, which requires further investigation. Our findings indicate that genetic factors responsible for AFFs are not widely shared among AFF cases. The study provides a stepping-stone for future larger genetic studies of AFF., Title in the list of papers of Joel Ås' thesis: Gene-based association analysis of a large patient cohort identifies potential gene candidates for atypical femur fractures

Published
2024
Full Text
View/download PDF

33. The NOS1AP gene rs10494366 common genetic variant does not modify the risk of sudden cardiac death in users of digoxin

Author

Soroush, Negin, Aarnoudse, Albert Jan, Kavousi, Maryam, Kors, Jan A., Ikram, M. Arfan, Stricker, Bruno H., Ahmadizar, Fariba, Soroush, Negin, Aarnoudse, Albert Jan, Kavousi, Maryam, Kors, Jan A., Ikram, M. Arfan, Stricker, Bruno H., and Ahmadizar, Fariba

Abstract

Aims: Common genetic variations in the nitric oxide synthase-1 adaptor protein (NOS1AP) gene are associated with QT-interval prolongation. In a previous study, we observed an association between the rs10494366 variant of this gene and an increased QT-interval shortening in digoxin users. As QT-interval shortening is a risk factor for sudden cardiac death (SCD), in this study, we investigated whether the association between digoxin use and risk of SCD differs in participants with different NOS1AP rs10494366 genotypes. Methods: We included 11 377 individuals from the prospective population-based cohort of the Rotterdam Study. We used Cox proportional hazard regression analysis with digoxin as time-dependent exposure to estimate the associations between current digoxin use and the risk of SCD among different rs10494366 genotype groups in the adjusted models. We also studied whether such an association was dose-dependent, comparing high dosage (≥ 0.250 mg), moderate dosage (0.125 mg ≤ dose< 0.250 mg) and low dosage (< 0.125 mg) digoxin users with non-users. Results: The median baseline age of the total study population was 62 (interquartile range [IQR] 58–71) years. The cumulative incidence of SCD was 4.1% (469 cases), and among them, 74 (15.7%) individuals were current digoxin users at the time of death, during a median follow-up of 11.5 (IQR 6.5–17) years. Current digoxin users had an increased risk of SCD (multivariable adjusted model hazard ratio [HR]: 3.07; 95% confidence interval [CI]: 2.38–3.98), with no significant differences between the three genotype groups. The adjusted HRs were 4.03 [95% CI: 1.98–8.21] in the minor homozygous GG, 3.46 [95% CI: 2.37–5.04] in the heterozygous TG and 2.56 [95%CI: 1.70–3.86] in the homozygous TT genotype groups. Compared to low- and moderate-dose, high-dose digoxin users with GG genotype had the highest risk of SCD (HR: 5.61 [95% CI: 1.34–23.47]). Conclusions: Current use of digoxin is associated with a significantly i

Published
2024

34. Association between long-term use of calcium channel blockers (CCB) and the risk of breast cancer:a retrospective longitudinal observational study protocol

Author

Ho, Chau, Ha, Ninh Thi, Youens, David, Abhayaratna, Walter P., Bulsara, Max K., Hughes, Jeffery David, Mishra, Gita, Pearson, Sallie Anne, Preen, David B., Reid, Christopher M., Ruiter, Rikje, Saunders, Christobel M., Stricker, Bruno H., van Rooij, Frank J.A., Wright, Cameron, Moorin, Rachael, Ho, Chau, Ha, Ninh Thi, Youens, David, Abhayaratna, Walter P., Bulsara, Max K., Hughes, Jeffery David, Mishra, Gita, Pearson, Sallie Anne, Preen, David B., Reid, Christopher M., Ruiter, Rikje, Saunders, Christobel M., Stricker, Bruno H., van Rooij, Frank J.A., Wright, Cameron, and Moorin, Rachael

Abstract

Introduction Calcium channel blockers (CCB), a commonly prescribed antihypertensive (AHT) medicine, may be associated with increased risk of breast cancer. The proposed study aims to examine whether long-term CCB use is associated with the development of breast cancer and to characterise the dose-response nature of any identified association, to inform future hypertension management. Methods and analysis The study will use data from 2 of Australia's largest cohort studies; the Australian Longitudinal Study on Women's Health, and the 45 and Up Study, combined with the Rotterdam Study. Eligible women will be those with diagnosed hypertension, no history of breast cancer and no prior CCB use at start of follow-up (2004-2009). Cumulative dose-duration exposure to CCB and other AHT medicines will be captured at the earliest date of: the outcome (a diagnosis of invasive breast cancer); a competing risk event (eg, bilateral mastectomy without a diagnosis of breast cancer, death prior to any diagnosis of breast cancer) or end of follow-up (censoring event). Fine and Gray competing risks regression will be used to assess the association between CCB use and development of breast cancer using a generalised propensity score to adjust for baseline covariates. Time-varying covariates related to interaction with health services will also be included in the model. Data will be harmonised across cohorts to achieve identical protocols and a two-step random effects individual patient-level meta-analysis will be used. Ethics and dissemination Ethical approval was obtained from the following Human research Ethics Committees: Curtin University (ref No. HRE2022-0335), NSW Population and Health Services Research Ethics Committee (2022/ETH01392/2022.31), ACT Research Ethics and Governance Office approval under National Mutual Acceptance for multijurisdictional data linkage research (2022.STE.00208). Results of the proposed study will be published in high-impact journals and presented at

Published
2024

35. Diuretic Use and Serum Phosphate:Rotterdam Study and UK Biobank

Author

Bosman, Ariadne, Campos-Obando, Natalia, De Keyser, Catherine E., Stricker, Bruno H., Zillikens, M. Carola, Bosman, Ariadne, Campos-Obando, Natalia, De Keyser, Catherine E., Stricker, Bruno H., and Zillikens, M. Carola

Abstract

Purpose: Hypophosphatemia (serum phosphate < 0.80 mmol/L) leads to musculoskeletal complaints. The most common drugs linked to hypophosphatemia are thiazide and loop diuretics, but studies in the general population are lacking. Our aim was to study associations between diuretic use and serum phosphate in the Rotterdam Study (RS), a population-based cohort study, with replication in UK Biobank (UKBB).Methods: Associations between thiazide and loop diuretic use and serum phosphate and odds of hypophosphatemia were analyzed with cross-sectional multivariate linear and logistic regression in participants without chronic kidney disease in the RS and UKBB. Analyses were adjusted for age, sex, and body mass index (BMI) and pooled in 3 RS cohorts with further adjustment for cohort and serum potassium, which was not available in UKBB. Results: Thiazide diuretics were associated with lower serum phosphate in both sexes. This association lost significance in RS females after adjustment for BMI and in males after adjustment for serum potassium. Thiazide diuretics increased odds of hypophosphatemia in females in both cohorts and in males in UKBB only. Loop diuretics were associated with lower serum phosphate in females but not males. Adjustment for BMI attenuated these associations. Associations between loop diuretics and increased odds of hypophosphatemia in females lost significance after BMI adjustment. Conclusion: Thiazides, but not loop diuretics, and increased BMI and decreased serum potassium should be considered as contributing factors in subjects with hypophosphatemia. Further studies are needed to replicate the findings and elucidate the potential role of hypokalemia as a mediator of this effect.

Published
2024

36. Association of blood cell-based inflammatory markers with gut microbiota and cancer incidence in the Rotterdam study

Author

Najjary, Shiva, Kros, Johan M., Stricker, Bruno H., Ruiter, Rikje, Shuai, Yu, Kraaij, Robert, Van Steen, Kristel, van der Spek, Peter, Van Eijck, Casper H.J., Ikram, M. Arfan, Ahmad, Shahzad, Najjary, Shiva, Kros, Johan M., Stricker, Bruno H., Ruiter, Rikje, Shuai, Yu, Kraaij, Robert, Van Steen, Kristel, van der Spek, Peter, Van Eijck, Casper H.J., Ikram, M. Arfan, and Ahmad, Shahzad

Abstract

The immune response–gut microbiota interaction is implicated in various human diseases, including cancer. Identifying the link between the gut microbiota and systemic inflammatory markers and their association with cancer will be important for our understanding of cancer etiology. The current study was performed on 8090 participants from the population-based Rotterdam study. We found a significant association (false discovery rate [FDR] ≤0.05) between lymphocytes and three gut microbial taxa, namely the family Streptococcaceae, genus Streptococcus, and order Lactobacillales. In addition, we identified 95 gut microbial taxa that were associated with inflammatory markers (p < 0.05). Analyzing the cancer data, we observed a significant association between higher systemic immune-inflammation index (SII) levels at baseline (hazard ratio (HR): 1.65 [95% confidence interval (CI); 1.10–2.46, p ≤ 0.05]) and a higher count of lymphocytes (HR: 1.38 [95% CI: 1.15–1.65, p ≤ 0.05]) and granulocytes (HR: 1.69 [95% CI: 1.40–2.03, p ≤ 0.05]) with increased risk of lung cancer after adjusting for age, sex, body mass index (BMI), and study cohort. This association was lost for SII and lymphocytes after additional adjustment for smoking (SII = HR:1.46 [95% CI: 0.96–2.22, p = 0.07] and lymphocytes = HR: 1.19 [95% CI: 0.97–1.46, p = 0.08]). In the stratified analysis, higher count of lymphocyte and granulocytes at baseline were associated with an increased risk of lung cancer in smokers after adjusting for age, sex, BMI, and study cohort (HR: 1.33 [95% CI: 1.09–1.62, p ≤0.05] and HR: 1.57 [95% CI: 1.28–1.92, p ≤0.05], respectively). Our study revealed a positive association between gut microbiota, higher SII levels, and higher lymphocyte and granulocyte counts, with an increased risk of developing lung cancer.

Published
2024

37. Antihypertensive Drugs for the Prevention of Atrial Fibrillation: A Drug Target Mendelian Randomization Study.

Author

Geurts, Sven, Tilly, Martijn J., Zuolin Lu, Stricker, Bruno H. C., Deckers, Jaap W., de Groot, Natasja M. S., Miller, Clint L., Ikram, M. Arfan, and Kavousi, Maryam

Abstract

BACKGROUND: We investigated the potential impact of antihypertensive drugs for atrial fibrillation (AF) prevention through a drug target Mendelian randomization study to avoid the potential limitations of clinical studies. METHODS: Validated published single-nucleotide polymorphisms (SNPs) that mimic the action of 12 antihypertensive drug classes, including alpha-adrenoceptor blockers, adrenergic neuron blockers, angiotensin-converting enzyme inhibitors, angiotensin-II receptor blockers, beta-adrenoceptor blockers, centrally acting antihypertensive drugs, calcium channel blockers, loop diuretics, potassium-sparing diuretics and mineralocorticoid receptor antagonists, renin inhibitors, thiazides and related diuretic agents, and vasodilators were used. We estimated, via their corresponding gene and protein targets, the downstream effect of these drug classes to prevent AF via systolic blood pressure using 2-sample Mendelian randomization analyses. The SNPs were extracted from 2 European genome-wide association studies for the drug classes (n=317 754; n=757 601) and 1 European genome-wide association study for AF (n=1 030 836). RESULTS: Drug target Mendelian randomization analyses supported the significant preventive causal effects of lowering systolic blood pressure per 10 mm Hg via alpha-adrenoceptor blockers (n=11 SNPs; odds ratio [OR], 0.34 [95% CI, 0.21-0.56]; P=2.74×10-05), beta-adrenoceptor blockers (n=17 SNPs; OR, 0.52 [95% CI, 0.35-0.78]; P=1.62×10-03), calcium channel blockers (n=49 SNPs; OR, 0.50 [95% CI, 0.36-0.70]; P=4.51×10-05), vasodilators (n=19 SNPs; OR, 0.53 [95% CI, 0.34-0.84]; P=7.03×10-03), and all 12 antihypertensive drug classes combined (n=158 SNPs; OR, 0.64 [95% CI, 0.54-0.77]; P=8.50×10-07) on AF risk. CONCLUSIONS: Our results indicated that lowering systolic blood pressure via protein targets of various antihypertensive drugs seems promising for AF prevention. Our findings inform future clinical trials and have implications for repurposing antihypertensive drugs for AF prevention. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

41. Association between long-term use of calcium channel blockers (CCB) and the risk of breast cancer: a retrospective longitudinal observational study protocol

Author

Ho, Chau, primary, Ha, Ninh Thi, additional, Youens, David, additional, Abhayaratna, Walter P, additional, Bulsara, Max K, additional, Hughes, Jeffery David, additional, Mishra, Gita, additional, Pearson, Sallie-Anne, additional, Preen, David B, additional, Reid, Christopher M, additional, Ruiter, Rikje, additional, Saunders, Christobel M, additional, Stricker, Bruno H, additional, van Rooij, Frank J A, additional, Wright, Cameron, additional, and Moorin, Rachael, additional

Published
2024
Full Text
View/download PDF

42. Association of blood cell‐based inflammatory markers with gut microbiota and cancer incidence in the Rotterdam study

Author

Najjary, Shiva, primary, Kros, Johan M., additional, Stricker, Bruno H., additional, Ruiter, Rikje, additional, Shuai, Yu, additional, Kraaij, Robert, additional, Van Steen, Kristel, additional, van der Spek, Peter, additional, Van Eijck, Casper H. J., additional, Ikram, M. Arfan, additional, and Ahmad, Shahzad, additional

Published
2024
Full Text
View/download PDF

43. Meta-analysis of genome-wide association studies of HDL cholesterol response to statins

Author

Postmus, Iris, Warren, Helen R, Trompet, Stella, Arsenault, Benoit J, Avery, Christy L, Bis, Joshua C, Chasman, Daniel I, de Keyser, Catherine E, Deshmukh, Harshal A, Evans, Daniel S, Feng, QiPing, Li, Xiaohui, Smit, Roelof AJ, Smith, Albert V, Sun, Fangui, Taylor, Kent D, Arnold, Alice M, Barnes, Michael R, Barratt, Bryan J, Betteridge, John, Boekholdt, S Matthijs, Boerwinkle, Eric, Buckley, Brendan M, Chen, Y-D Ida, de Craen, Anton JM, Cummings, Steven R, Denny, Joshua C, Dubé, Marie Pierre, Durrington, Paul N, Eiriksdottir, Gudny, Ford, Ian, Guo, Xiuqing, Harris, Tamara B, Heckbert, Susan R, Hofman, Albert, Hovingh, G Kees, Kastelein, John JP, Launer, Leonore J, Liu, Ching-Ti, Liu, Yongmei, Lumley, Thomas, McKeigue, Paul M, Munroe, Patricia B, Neil, Andrew, Nickerson, Deborah A, Nyberg, Fredrik, O'Brien, Eoin, O'Donnell, Christopher J, Post, Wendy, Poulter, Neil, Vasan, Ramachandran S, Rice, Kenneth, Rich, Stephen S, Rivadeneira, Fernando, Sattar, Naveed, Sever, Peter, Shaw-Hawkins, Sue, Shields, Denis C, Slagboom, P Eline, Smith, Nicholas L, Smith, Joshua D, Sotoodehnia, Nona, Stanton, Alice, Stott, David J, Stricker, Bruno H, Stürmer, Til, Uitterlinden, André G, Wei, Wei-Qi, Westendorp, Rudi GJ, Whitsel, Eric A, Wiggins, Kerri L, Wilke, Russell A, Ballantyne, Christie M, Colhoun, Helen M, Cupples, L Adrienne, Franco, Oscar H, Gudnason, Vilmundur, Hitman, Graham, Palmer, Colin NA, Psaty, Bruce M, Ridker, Paul M, Stafford, Jeanette M, Stein, Charles M, Tardif, Jean-Claude, Caulfield, Mark J, Jukema, J Wouter, Rotter, Jerome I, and Krauss, Ronald M

Subjects
Atherosclerosis, Genetics, Human Genome, Aetiology, 2.1 Biological and endogenous factors, Stroke, Good Health and Well Being, Cholesterol Ester Transfer Proteins, Cholesterol, HDL, Female, Genome-Wide Association Study, Humans, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Male, Pharmacogenomic Variants, Polymorphism, Single Nucleotide, Treatment Outcome, White People, Genome-wide association study, HDL-cholesterol, Statins, pharmacogenetics, Biological Sciences, Medical and Health Sciences, Genetics & Heredity
Abstract

BackgroundIn addition to lowering low density lipoprotein cholesterol (LDL-C), statin therapy also raises high density lipoprotein cholesterol (HDL-C) levels. Inter-individual variation in HDL-C response to statins may be partially explained by genetic variation.Methods and resultsWe performed a meta-analysis of genome-wide association studies (GWAS) to identify variants with an effect on statin-induced high density lipoprotein cholesterol (HDL-C) changes. The 123 most promising signals with p

Published
2016

44. Gene-gene Interaction Analyses for Atrial Fibrillation

Author

Lin, Honghuang, Mueller-Nurasyid, Martina, Smith, Albert V, Arking, Dan E, Barnard, John, Bartz, Traci M, Lunetta, Kathryn L, Lohman, Kurt, Kleber, Marcus E, Lubitz, Steven A, Geelhoed, Bastiaan, Trompet, Stella, Niemeijer, Maartje N, Kacprowski, Tim, Chasman, Daniel I, Klarin, Derek, Sinner, Moritz F, Waldenberger, Melanie, Meitinger, Thomas, Harris, Tamara B, Launer, Lenore J, Soliman, Elsayed Z, Chen, Lin Y, Smith, Jonathan D, Van Wagoner, David R, Rotter, Jerome I, Psaty, Bruce M, Xie, Zhijun, Hendricks, Audrey E, Ding, Jingzhong, Delgado, Graciela E, Verweij, Niek, van der Harst, Pim, Macfarlane, Peter W, Ford, Ian, Hofman, Albert, Uitterlinden, André, Heeringa, Jan, Franco, Oscar H, Kors, Jan A, Weiss, Stefan, Völzke, Henry, Rose, Lynda M, Natarajan, Pradeep, Kathiresan, Sekar, Kääb, Stefan, Gudnason, Vilmundur, Alonso, Alvaro, Chung, Mina K, Heckbert, Susan R, Benjamin, Emelia J, Liu, Yongmei, März, Winfried, Rienstra, Michiel, Jukema, J Wouter, Stricker, Bruno H, Dörr, Marcus, Albert, Christine M, and Ellinor, Patrick T

Subjects
Epidemiology, Biological Sciences, Health Sciences, Genetics, Heart Disease, Human Genome, Cardiovascular, Aetiology, 2.1 Biological and endogenous factors, Aged, Atrial Fibrillation, Cohort Studies, Epistasis, Genetic, Female, Genetic Association Studies, Genetic Predisposition to Disease, Genome-Wide Association Study, Genotype, Humans, Hyperpolarization-Activated Cyclic Nucleotide-Gated Channels, Male, Membrane Transport Proteins, Middle Aged, Multivariate Analysis, Muscle Proteins, Oligonucleotide Array Sequence Analysis, Polymorphism, Single Nucleotide, Potassium Channels
Abstract

Atrial fibrillation (AF) is a heritable disease that affects more than thirty million individuals worldwide. Extensive efforts have been devoted to the study of genetic determinants of AF. The objective of our study is to examine the effect of gene-gene interaction on AF susceptibility. We performed a large-scale association analysis of gene-gene interactions with AF in 8,173 AF cases, and 65,237 AF-free referents collected from 15 studies for discovery. We examined putative interactions between genome-wide SNPs and 17 known AF-related SNPs. The top interactions were then tested for association in an independent cohort for replication, which included more than 2,363 AF cases and 114,746 AF-free referents. One interaction, between rs7164883 at the HCN4 locus and rs4980345 at the SLC28A1 locus, was found to be significantly associated with AF in the discovery cohorts (interaction OR = 1.44, 95% CI: 1.27-1.65, P = 4.3 × 10-8). Eight additional gene-gene interactions were also marginally significant (P

Published
2016

48. Integration of epidemiologic, pharmacologic, genetic and gut microbiome data in a drug–metabolite atlas

Author

Liu, Jun, Lahousse, Lies, Nivard, Michel G., Bot, Mariska, Chen, Lianmin, van Klinken, Jan Bert, Thesing, Carisha S., Beekman, Marian, van den Akker, Erik Ben, Slieker, Roderick C., Waterham, Eveline, van der Kallen, Carla J. H., de Boer, Irene, Li-Gao, Ruifang, Vojinovic, Dina, Amin, Najaf, Radjabzadeh, Djawad, Kraaij, Robert, Alferink, Louise J. M., Murad, Sarwa Darwish, Uitterlinden, André G., Willemsen, Gonneke, Pool, Rene, Milaneschi, Yuri, van Heemst, Diana, Suchiman, H. Eka D., Rutters, Femke, Elders, Petra J. M., Beulens, Joline W. J., van der Heijden, Amber A. W. A., van Greevenbroek, Marleen M. J., Arts, Ilja C. W., Onderwater, Gerrit L. J., van den Maagdenberg, Arn M. J. M., Mook-Kanamori, Dennis O., Hankemeier, Thomas, Terwindt, Gisela M., Stehouwer, Coen D. A., Geleijnse, Johanna M., ‘t Hart, Leen M., Slagboom, P. Eline, van Dijk, Ko Willems, Zhernakova, Alexandra, Fu, Jingyuan, Penninx, Brenda W. J. H., Boomsma, Dorret I., Demirkan, Ayşe, Stricker, Bruno H. C., and van Duijn, Cornelia M.

Published
2020
Full Text
View/download PDF

49. Drug-Gene Interactions of Antihypertensive Medications and Risk of Incident Cardiovascular Disease: A Pharmacogenomics Study from the CHARGE Consortium.

Author

Bis, Joshua C, Sitlani, Colleen, Irvin, Ryan, Avery, Christy L, Smith, Albert Vernon, Sun, Fangui, Evans, Daniel S, Musani, Solomon K, Li, Xiaohui, Trompet, Stella, Krijthe, Bouwe P, Harris, Tamara B, Quibrera, P Miguel, Brody, Jennifer A, Demissie, Serkalem, Davis, Barry R, Wiggins, Kerri L, Tranah, Gregory J, Lange, Leslie A, Sotoodehnia, Nona, Stott, David J, Franco, Oscar H, Launer, Lenore J, Stürmer, Til, Taylor, Kent D, Cupples, L Adrienne, Eckfeldt, John H, Smith, Nicholas L, Liu, Yongmei, Wilson, James G, Heckbert, Susan R, Buckley, Brendan M, Ikram, M Arfan, Boerwinkle, Eric, Chen, Yii-Der Ida, de Craen, Anton JM, Uitterlinden, Andre G, Rotter, Jerome I, Ford, Ian, Hofman, Albert, Sattar, Naveed, Slagboom, P Eline, Westendorp, Rudi GJ, Gudnason, Vilmundur, Vasan, Ramachandran S, Lumley, Thomas, Cummings, Steven R, Taylor, Herman A, Post, Wendy, Jukema, J Wouter, Stricker, Bruno H, Whitsel, Eric A, Psaty, Bruce M, and Arnett, Donna

Subjects
Humans, Cardiovascular Diseases, Hypertension, Antihypertensive Agents, Treatment Outcome, Incidence, Polymorphism, Single Nucleotide, Aged, Middle Aged, African Americans, European Continental Ancestry Group, Female, Male, Genome-Wide Association Study, Polymorphism, Single Nucleotide, General Science & Technology
Abstract

BackgroundHypertension is a major risk factor for a spectrum of cardiovascular diseases (CVD), including myocardial infarction, sudden death, and stroke. In the US, over 65 million people have high blood pressure and a large proportion of these individuals are prescribed antihypertensive medications. Although large long-term clinical trials conducted in the last several decades have identified a number of effective antihypertensive treatments that reduce the risk of future clinical complications, responses to therapy and protection from cardiovascular events vary among individuals.MethodsUsing a genome-wide association study among 21,267 participants with pharmaceutically treated hypertension, we explored the hypothesis that genetic variants might influence or modify the effectiveness of common antihypertensive therapies on the risk of major cardiovascular outcomes. The classes of drug treatments included angiotensin-converting enzyme inhibitors, beta-blockers, calcium channel blockers, and diuretics. In the setting of the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) consortium, each study performed array-based genome-wide genotyping, imputed to HapMap Phase II reference panels, and used additive genetic models in proportional hazards or logistic regression models to evaluate drug-gene interactions for each of four therapeutic drug classes. We used meta-analysis to combine study-specific interaction estimates for approximately 2 million single nucleotide polymorphisms (SNPs) in a discovery analysis among 15,375 European Ancestry participants (3,527 CVD cases) with targeted follow-up in a case-only study of 1,751 European Ancestry GenHAT participants as well as among 4,141 African-Americans (1,267 CVD cases).ResultsAlthough drug-SNP interactions were biologically plausible, exposures and outcomes were well measured, and power was sufficient to detect modest interactions, we did not identify any statistically significant interactions from the four antihypertensive therapy meta-analyses (Pinteraction > 5.0×10-8). Similarly, findings were null for meta-analyses restricted to 66 SNPs with significant main effects on coronary artery disease or blood pressure from large published genome-wide association studies (Pinteraction ≥ 0.01). Our results suggest that there are no major pharmacogenetic influences of common SNPs on the relationship between blood pressure medications and the risk of incident CVD.

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results